Discovery of a Potent, Orally Bioavailable Small-Molecule Inhibitor of Wildtype KIT with Exceptionally High Kinome Selectivity

Key Points

The research aims to identify a potent small-molecule inhibitor specifically targeting wildtype KIT.
Evaluated in an SCF-driven acute cutaneous anaphylaxis model in rodents.
Assessed the orally bioavailable properties and kinome selectivity of the inhibitor.
Showed significant therapeutic efficacy in reducing symptoms of acute cutaneous anaphylaxis.
Demonstrated high kinome selectivity, minimizing effects on other kinases.

We only have this paper's title and publication details.

therapeutic efficacy in an SCF-driven acute cutaneous anaphylaxis model in rodents.

No takes yet. Share an insight, caveat, or question.

Chen et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share